AMLX vs TPR · $561.6M cap vs P/E 46, rev $8.00B
Amylyx Pharmaceuticals Inc (AMLX) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
AMLX currently screens at market cap $561.6M. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the AMLX and TPR stock pages for the full models.
Not investment advice.